Cencora Competitive Intelligence & Landscape

Cencora (cencora.com) is a global healthcare solutions leader focused on improving the lives of people and animals through innovative partnerships with manufacturers, providers, and pharmacies. The company offers a comprehensive range of solutions encompassing distribution, commercialization, patient access, and pharmacy solutions. Their mission is to create healthier futures by helping bring innovations to market and improve care delivery worldwide, acting as a critical link between pharmaceutical manufacturers and healthcare providers.

Cencora's core services include logistics and warehousing, drug research and clinical development, commercialization support, and patient access and adherence support for manufacturers. For providers, they offer wholesale and specialty distribution, pharmacy solutions, and tailored solutions for physician practices, clinics, hospitals, and health systems. Their expertise spans biosimilar commercialization, cell and gene therapies, OTC & consumer healthcare products, oncology, brand and specialty products, global generic products, and mature product outsourcing.

The company targets a broad market including pharmaceutical manufacturers, healthcare providers, pharmacies, health systems, physician practices, clinics, and government entities.

Cencora was established in 2023, building upon a legacy of over 100 years of progress and excellence in pharmaceutical sourcing and wholesale distribution under its former name, AmerisourceBergen. While its headquarters are not explicitly stated on the provided pages, it operates with a global reach across North and South America, Europe, and Asia Pacific.

Cencora emphasizes its role in empowering patient-centered care and ensuring patients can get the medications they need. The company prides itself on a legacy of execution excellence, strategic corporate stewardship, and shareholder value creation, as evidenced by its investor relations information. It is also committed to corporate responsibility, highlighting its purpose-driven team members, healthy communities, and resilient and sustainable operations.

Cencora offers various solutions that provide economic advantages and support for its partners, though specific pricing plans and tiers are not explicitly detailed as a traditional product. Their PRxO Generics program offers economically competitive drug choices, margin-improving solutions, and performance-based rebates on a broad portfolio of generic drugs, featuring competitive invoice pricing for managing near-term cash flow and automated margin enhancement. This program focuses on helping customers make smart purchasing decisions and simplify operations through reliable daily delivery [https://www.cencora.com/-/media/assets/corporate/global/pdfs/biopharm_337_prxo_generics_brochure_aug_2025_fn.pdf].

For manufacturers, Cencora's Full Order-to-Cash Solution provides managed end-to-end fulfillment services, allowing pharmaceutical manufacturers to avoid the added risk and costs associated with customer management and order fulfillment [https://www.cencora.com/solutions/full-order-to-cash-solution]. Similarly, the Sure Supply program helps maintain uninterrupted access to shortage-prone medications with dedicated six-month inventory reserves, offering predictable costs and reliable supply even when market shortages disrupt competitors [https://www.cencora.com/solutions/sure-supply]. These solutions are designed to streamline operations and manage risk, implying a service-based pricing model rather than fixed product tiers.

Cencora also offers solutions aimed at reducing waste and helping customers save money. The Short Dates and Special Buys solution, launched in July 2022, provides pharmacies access to discounted generic injectables and other products, which has saved nearly 500 customers over $9.6 million by offering access to over 180 products in its first two years [https://www.cencora.com/resources/human-health/short-dates-special-buys]. This program demonstrates Cencora's commitment to providing cost-saving opportunities.

Furthermore, Cencora's Real-Time Prescription Benefit (RTPB) and Cencora Benefit eServices are designed to reduce abandonment and improve adherence by providing real-time, patient-specific benefits, out-of-pocket costs, and covered alternatives directly in the prescribing workflow [https://www.cencora.com/solutions/real-time-prescription-benefit][https://www.cencora.com/solutions/cencora-benefit-eservices]. While these are solutions to improve efficiency and patient outcomes, specific pricing models for these services are not publicly detailed on their website. Their Third-Party Logistics Technology Solutions also aim to increase visibility, efficiency, and collaboration within the pharmaceutical supply chain through data-driven tools [https://www.cencora.com/solutions/third-party-logistics-technology-solutions].

Cencora (cencora.com) actively promotes a culture of career activation and growth, positioning itself as a

Cencora, formerly known as AmerisourceBergen, demonstrates strong financial performance as a global healthcare solutions leader. For the fiscal year 2024, the company reported a substantial revenue of $294.0 billion, marking a 12.1 percent year-over-year increase. Its fourth-quarter revenue in fiscal year 2024 reached $79.1 billion, representing a 14.7 percent increase compared to the prior year [https://investor.cencora.com/news/news-details/2024/Cencora-Reports-Fiscal-2024-Fourth-Quarter-and-Year-End-Results/default.aspx].

Continuing this growth, Cencora's fiscal year 2025 saw revenue climb to $321.3 billion, a 9.3 percent increase year-over-year. In the fourth quarter of fiscal year 2025, revenue was $83.7 billion, up 5.9 percent from the previous year [https://investor.cencora.com/news/news-details/2025/Cencora-Reports-Fiscal-2025-Fourth-Quarter-and-Fiscal-Year-End-Results/default.aspx]. The company's financial health indicators also show positive trends, with diluted earnings per share (EPS) for the first quarter of fiscal 2026 at $2.87, compared to $2.50 in the prior year [https://investor.cencora.com/news/news-details/2026/Cencora-Reports-Fiscal-2026-First-Quarter-Results/default.aspx].

In terms of fundraising and financing activities, Cencora successfully closed a public offering of senior notes. This included $500 million aggregate principal amount of its 4.625% Senior Notes due December 15, 2027, $600 million aggregate principal amount of its 4.850% Senior Notes due December 15, 2029, and $700 million aggregate principal amount of its 5.150% Senior Notes due February 15, 2035 [https://investor.cencora.com/news/news-details/2024/Cencora-Closes-1.8-Billion-Senior-Notes-Offering/default.aspx]. This senior notes offering amounted to $1.8 billion, demonstrating the company's ability to secure significant capital [https://investor.cencora.com/news/news-details/2024/Cencora-Closes-1.8-Billion-Senior-Notes-Offering/default.aspx].

Recent quarterly results further highlight Cencora's consistent performance. For the first quarter of fiscal year 2026, revenue reached $85.9 billion, a 5.5% increase year-over-year [https://investor.cencora.com/news/news-details/2026/Cencora-Reports-Fiscal-2026-First-Quarter-Results/default.aspx]. In the second quarter of fiscal year 2026, revenue was $78.4 billion, reflecting a 3.8 percent increase year-over-year, with diluted EPS at $8.40 compared to $3.68 in the prior year's second quarter [https://investor.cencora.com/news/news-details/2026/Cencora-Reports-Fiscal-2026-Second-Quarter-Results/default.aspx]. These figures underscore Cencora's strategic corporate stewardship and commitment to shareholder value creation [https://investor.cencora.com/overview/default.aspx].

Cencora (cencora.com) actively participates in and hosts a variety of industry events to engage with healthcare and biopharmaceutical leaders. The company hosts its own Cencora ThinkLive Cell and Gene Therapy Summit, a two-day event bringing together industry leaders to discuss strategies across the product lifecycle, from R&D to global commercialization, with a focus on building sustainable solutions for future therapies [https://www.cencora.com/-/media/assets/corporate/global/event-pages/cgt-summit-2025/25-gps-00115-cencora-thinklive-cgt-summit-2025-agenda.pdf]. This summit includes discussions on engaging stakeholders to articulate the value of Cell and Gene Therapies (CGT) [https://www.cencora.com/-/media/assets/corporate/global/event-pages/cgt-summit-2025/25-gps-00115-cencora-thinklive-cgt-summit-2025-agenda.pdf].

Cencora also engages with the Closer to Science Global Trial Executive Exchange, which convenes senior leaders for peer-level conversations on optimizing global trial design to enhance regulatory approval, market access, and long-term asset value within a complex macroeconomic and regulatory environment [https://www.cencora.com/events/pharma/closer-to-science-global-trial]. Furthermore, Cencora actively participates in significant industry conferences such as the AMCP Annual, where they highlight thought leadership, research, and innovative biopharma solutions [https://www.cencora.com/events/pharma/amcp-annual].

In addition to hosting and participating in these events, Cencora attends major conferences like RAPS Convergence, a leading gathering for regulatory professionals [https://www.cencora.com/events/pharma/raps-convergence], and DIA Europe, which focuses on accelerating patient access and innovation in the life sciences sector [https://www.cencora.com/events/pharma/dia-europe]. The company also organizes networking events, such as the Asembia Client Reception, providing opportunities for industry leaders to connect during the Asembia conference [https://www.cencora.com/events/pharma/asembia/client-reception-rsvp-2026].

Cencora extends its educational outreach through events like the Alliance Healthcare Highlights Symposium, which offers accredited continuing education for various pharmaceutical staff on key topics [https://www.cencora.com/events/pharma/alliance-healthcare-highlights-symposium]. They also engage with industry partners to refine distribution and channel strategies at specialized events [https://www.cencora.com/events/pharma/trade-and-channel].

Cencora maintains an archive of past presentations and events, including their Q2 FY26 Earnings Call and participation in the BofA Securities 2026 Health Care Conference [https://investor.cencora.com/presentations-and-events/default.aspx].